Publications
Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleMorales PA, Korbel J, Rosas FE, 2023,
Thermodynamics of exponential Kolmogorov-Nagumo averages
, New Journal of Physics, Vol: 25, ISSN: 1367-2630This paper investigates generalized thermodynamic relationships in physical systems where relevant macroscopic variables are determined by the exponential Kolmogorov–Nagumo average. We show that while the thermodynamic entropy of such systems is naturally described by Rényi's entropy with parameter γ, an ordinary Boltzmann distribution still describes their statistics under equilibrium thermodynamics. Our results show that systems described by exponential Kolmogorov–Nagumo averages can be interpreted as systems originally in thermal equilibrium with a heat reservoir with inverse temperature β that are suddenly quenched to another heat reservoir with inverse temperature $\beta^{^{\prime}} = (1-\gamma)\beta$. Furthermore, we show the connection with multifractal thermodynamics. For the non-equilibrium case, we show that the dynamics of systems described by exponential Kolmogorov–Nagumo averages still observe a second law of thermodynamics and the H-theorem. We further discuss the applications of stochastic thermodynamics in those systems—namely, the validity of fluctuation theorems—and the connection with thermodynamic length.
-
Journal articleWeiss B, Erritzoe D, Giribaldi B, et al., 2023,
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression
, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 37, Pages: 717-732, ISSN: 0269-8811- Author Web Link
- Cite
- Citations: 2
-
Journal articleDelli Pizzi S, Chiacchiaretta P, Sestieri C, et al., 2023,
Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression
, BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, Vol: 8, Pages: 768-776, ISSN: 2451-9022 -
Journal articleLuppi AI, Hansen JY, Adapa R, et al., 2023,
In vivo mapping of pharmacologically induced functional reorganization onto the human brain's neurotransmitter landscape
, SCIENCE ADVANCES, Vol: 9, ISSN: 2375-2548 -
Journal articleJauhar S, Arnone D, Baldwin DS, et al., 2023,
A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression
, MOLECULAR PSYCHIATRY, ISSN: 1359-4184- Author Web Link
- Cite
- Citations: 1
-
Journal articleRabiner EA, Agnorelli C, Howes O, et al., 2023,
Reply to: No Clear Evidence of Reduced Brain Serotonin Release Capacity in Patients With Depression
, BIOLOGICAL PSYCHIATRY, Vol: 93, Pages: E53-E54, ISSN: 0006-3223 -
Journal articleErritzoe D, Godlewska BR, Rizzo G, et al., 2023,
Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge
, BIOLOGICAL PSYCHIATRY, Vol: 93, Pages: 1089-1098, ISSN: 0006-3223- Author Web Link
- Cite
- Citations: 13
-
Journal articleZafar R, 2023,
Psychedelic therapy in the treatment of addiction: the past, present and future
, Frontiers in Psychiatry, Vol: 14, Pages: 1-24, ISSN: 1664-0640Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction (Nutt, Spriggs and Erritzoe, 2023). In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the current socioeconomic impact of addiction, treatment options, and outcomes. We will start by examining historical studies from the first psychedelic research era of the mid-late 1900s, followed by an overview of the available real-world evidence gathered from naturalistic, observational, and survey-based studies. We will then cover modern-day clinical trials of psychedelic therapies in addiction from first-in-human to phase II clinical trials. Finally, we will provide an overview of the different translational human neuropsychopharmacology techniques, including functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), that can be applied to foster a mechanistic understanding of therapeutic mechanisms. A more granular understanding of the treatment effects of psychedelics will facilitate the optimisation of the psychedelic therapy drug development landscape, and ultimately improve patient outcomes.
-
Journal articleWeiss B, Wingert A, Erritzoe D, et al., 2023,
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca
, Scientific Reports, Vol: 13, Pages: 1-17, ISSN: 2045-2322The present study examined the safety and efficacy of the ceremonial use of ayahuasca in relation to reports of heightened life event reexperiencing under psychedelics. The study examined (1) the prevalence of specific types of adverse life event reexperiencing, (2) characteristics predictive of reexperiencing, (3) the psychological character of reexperiencing, and (4) the impact of reexperiencing on mental health. Participants were recruited from three ayahuasca healing and spiritual centers in South and Central America (N = 33 military veterans, 306 non-veterans) using self-report data at three timepoints (Pre-retreat, Post-retreat, 3-months post-retreat). Reexperiencing adverse life events under ayahuasca was common, with women showing particularly high probability of reexperiencing sexual assault, veterans reexperiencing combat-related trauma, and individuals with a self-reported lifetime diagnosis of post-traumatic stress disorder exhibiting a substantively higher prevalence of reexperiencing. Reexperiencing was associated with states of reappraisal, psychological flexibility, and discomfort during ceremony, and incremental reductions in trait neuroticism. Clinical implications of these results for the application of psychedelics to mood and stress disorders are discussed.
-
Journal articleAday JS, Carhart-Harris RL, Woolley JD, 2023,
Emerging Challenges for Psychedelic Therapy.
, JAMA Psychiatry, Vol: 80, Pages: 533-534
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.